Airway Responses to Montelukast and Desloratadine.

NCT ID: NCT00424580

Last Updated: 2008-01-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

12 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-01-31

Study Completion Date

2007-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Montelukast (for asthma) and desloratadine (for allergies) are effective therapy for their current uses. Part of what happens when your allergies trigger your asthma should be prevented by either of these drugs. This project is being conducted to determine if these drugs are effective, either alone or in combination, on controlling asthma that is triggered by allergies.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Asthma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Montelukast (10mg) and Desloratadine (5mg)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* baseline FEV1 \> or = 65% predicted
* positive methacholine challenge (i.e. methacholine PC20 \< or = 16mg/ml
* positive allergen challenge

Exclusion Criteria

* negative skin prick test
* lung condition/disease other than asthma
* currently use montelukast and/or desloratadine
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Saskatchewan

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Department of Medicine, University of Saskatchewan

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Donald W Cockcroft, MD, FRCP(C)

Role: PRINCIPAL_INVESTIGATOR

University of Saskatchew Full Professor

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Room 346 Ellis Hall

Saskatoon, Saskatchewan, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Canada

References

Explore related publications, articles, or registry entries linked to this study.

Davis BE, Illamperuma C, Gauvreau GM, Watson RM, O'Byrne PM, Deschesnes F, Boulet LP, Cockcroft DW. Single-dose desloratadine and montelukast and allergen-induced late airway responses. Eur Respir J. 2009 Jun;33(6):1302-8. doi: 10.1183/09031936.00169008. Epub 2009 Jan 22.

Reference Type DERIVED
PMID: 19164343 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

BIO-REB# 06-232

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Montelukast With Status Asthmaticus, Ages 2-5
NCT00491790 UNKNOWN PHASE2/PHASE3
Acute Montelukast in Asthma
NCT01011452 COMPLETED PHASE4